Bevacizumab biosimilar - Pfizer

Drug Profile

Bevacizumab biosimilar - Pfizer

Alternative Names: PF-06439535; PF-6439535

Latest Information Update: 24 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 01 Apr 2015 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Ukraine, Turkey, Thailand, Taiwan, Australia, Chile, Croatia, Czech Republic, France, Germany, Greece, Hungary, Japan, Italy, South Korea, Malaysia, Netherlands, Philippines, Poland, Romania, Russia, Spain, South Africa, Slovakia (IV) after April 2015
  • 01 Apr 2015 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in USA (IV) (NCT02364999)
  • 24 Feb 2015 Pfizer plans a phase III trial for Non-small cell lung cancer (First-line therapy; Late-stage disease; Unresectable/Inoperable; Recurrent; Combination therapy) in USA (NCT02364999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top